Abstract Number: 3179 • 2016 ACR/ARHP Annual Meeting
Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Background/Purpose: Candidate questionnaire items were produced following in-depth qualitative research in the UK, US, and Canada plus cognitive interviews, extensive piloting and independent linguistic and…Abstract Number: 980 • 2016 ACR/ARHP Annual Meeting
Short-Course Glucocorticoids in ANCA-Associated Vasculitis: A Proof of Concept Study
Background/Purpose: Despite therapeutic advances in ANCA-associated vasculitis (AAV), patients continue to be exposed to considerable treatment morbidity from long-term glucocorticoid (GC) use. The optimal duration…Abstract Number: 1943 • 2016 ACR/ARHP Annual Meeting
Factors Predictive of ANCA-Associated Vasculitis Relapse
Background/Purpose: To identify associations between patients’ clinical and biological characteristics at diagnosis of antineutrophil cytoplasmic antibody-associated vasculitides (AAVs), and their relapse during follow-up. Methods: Long-term…Abstract Number: 3180 • 2016 ACR/ARHP Annual Meeting
Utility of Measurements of Urinary Soluble CD163 & MCP-1 in the Identification of Subtle Renal Flares in ANCA-Associated Vasculitis
Background/Purpose: Prior work has shown that urinary soluble CD163 (usCD163) displays excellent biomarker characteristics for detection of active renal vasculitis using samples from patients with…Abstract Number: 999 • 2016 ACR/ARHP Annual Meeting
Utility of Neutrophil CD64 Expression & sTREM-1 in Distinguishing Bacterial Infection from Disease Flare in SLE and ANCA Associated Vasculitis
Background/Purpose: Fever is a common presenting manifestation of systemic lupus erythematosus (SLE) and ANCA associated vasculitis (AAV). Treating physician is challenged to differentiate between disease…Abstract Number: 1944 • 2016 ACR/ARHP Annual Meeting
Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA-Associated Vasculitis
Background/Purpose: ANCA-associated vasculitis (AAV) treatment includes high dose glucocorticoids (GCs), which are associated with increased body-mass index (BMI), a complication abhorred by patients and associated…Abstract Number: 1215 • 2016 ACR/ARHP Annual Meeting
Interferon Signature Genes Are Differentially Expressed Between Microscopic Polyangiitis and Systemic Lupus Erythematosus Peripheral Blood Transcriptomes
Background/Purpose: Interferon (IFN) signature has been established in the peripheral blood of the patients with systemic lupus erythematosus (SLE) by transcriptome analyses, indicating a role…Abstract Number: 1945 • 2016 ACR/ARHP Annual Meeting
Development and Validation of Case-Finding Algorithms for the Identification of Patients with ANCA-Associated Vasculitis and Large-Vessel Vasculitis in Healthcare Administrative Databases
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of vasculitides that consists of granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA), and microscopic polyangiitis…Abstract Number: 1923 • 2016 ACR/ARHP Annual Meeting
Activated Partial Thromboplastin Time Reflects Disease Activity in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of systemic vasculitides associated with ANCA specific for myeloperoxidase (MPO) or proteinase-3 (PR3), and includes…Abstract Number: 1947 • 2016 ACR/ARHP Annual Meeting
Ocular Manifestations of ANCA-Associated Vasculitis
Background/Purpose: Ocular involvement in ANCA-associated vasculitis (AAV) can cause substantial morbidity. We aimed to characterize patterns of ocular involvement in AAV and their response to…Abstract Number: 1925 • 2016 ACR/ARHP Annual Meeting
Interest of Procalcitonin for the Follow-up of ANCA-Associated Vasculitis: Data from a Cohort of 99 Patients
Background/Purpose: The prognosis of the ANCA associated vasculitis (AAV) has improved with the new immunosuppressive treatments but infectious complications remain frequent. Procalcitonin (PCT) is…Abstract Number: 1949 • 2016 ACR/ARHP Annual Meeting
Presentation, Prognosis and Clinical-Pathological Correlations of Cutaneous Manifestations in ANCA-Associated Vasculitides
Background/Purpose: Cutaneous involvement is frequent during ANCA-associated vasculitis (AAV) and can reveal the disease. However, no large study on presentation and clinical-pathological correlations is available.…Abstract Number: 1926 • 2016 ACR/ARHP Annual Meeting
Indications for Testing and Diagnostic Outcome in Patients with Positive ANCA at a Canadian Tertiary Care Centre
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) are a hallmark of a subset of small vasculitides collectively termed ANCA-associated vasculitis (AAV). With widespread availability of ANCA testing,…Abstract Number: 1950 • 2016 ACR/ARHP Annual Meeting
ANCA-Associated Vasculitides and IgG4-Related Disease: An Overlapping Syndrome? a European Observational Study of 18 Patients
Background/Purpose: Atypical manifestations have been described in patients with antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV), such as periaortic fibrosis, pachymeningitis and orbital mass. Because these…Abstract Number: 1929 • 2016 ACR/ARHP Annual Meeting
Comparison of Two Different ANCA Iif Methods with EIA and Disease Phenotype
Background/Purpose: ANCAs are used as diagnostic markers in patients with autoimmune vasculitis such as Granulomatosis with polyangitis (GPA), Microscopic polyangitis (MPA), and Eosinophilic granulomatosis with…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 20
- Next Page »